Antiplatelet Agents, Anticoagulants, and Specific Thrombin Inhibitors

Part of the Contemporary Cardiology book series (CONCARD)


Antiplatelet agents are used in virtually all patients with coronary heart disease (CHD). Aspirin, the pioneer hallmark agent, is of proven value for the management of
  • Acute myocardial infarction (MI).

  • Post-MI prophylaxis.

  • Unstable angina.

  • Stable angina.

  • Following coronary artery bypass graft (CABG) and coronary angioplasty.

  • Coronary stents when combined with clopidogrel.

  • Lone atrial fibrillation in individuals aged < 65 yr.

  • Transient ischemic attacks (TIAs) or following nonhemorrhagic stroke.


Acute Coronary Syndrome International Normalize Ratio Unstable Angina Oral Anticoagulant Antiplatelet Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897.CrossRefGoogle Scholar
  2. 2.
    Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137.PubMedCrossRefGoogle Scholar
  3. 3.
    Sherman CT, Litrack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:913.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396.PubMedCrossRefGoogle Scholar
  5. 5.
    SIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:350.Google Scholar
  6. 6.
    Clarke RJ, Mago G, Fitzgerald G, et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510.PubMedGoogle Scholar
  7. 7.
    Khan M Gabriel, Topol EJ. Complications of myocardial infarction. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.Google Scholar
  8. 8.
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 1986; 313:1369.CrossRefGoogle Scholar
  9. 9.
    Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Valley Med J 1953;75:38.PubMedGoogle Scholar
  10. 10.
    Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974;1:436.PubMedCrossRefGoogle Scholar
  11. 11.
    Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8:301.PubMedGoogle Scholar
  12. 12.
    Canadian Cooperative Study Group. Arandomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53.CrossRefGoogle Scholar
  13. 13.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349.Google Scholar
  14. 14.
    Resnekov L, Chekiak J, Hirsh J, et al. Antithrombotic agents in coronary artery disease. Chest 1989;95: 528.Google Scholar
  15. 15.
    Juul-Moller S, Edvardsson N, Jhnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;40:1421.CrossRefGoogle Scholar
  16. 16.
    Albers GW. Atrial fibrillation and stroke: Three new studies, three remaining questions. Arch Intern Med 1994;154:1443.PubMedCrossRefGoogle Scholar
  17. 17.
    Atrial Fibrillation Investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from 5 randomized controlled trials. Arch Intern Med 1994;154:1449.CrossRefGoogle Scholar
  18. 18.
    Patrono C, Wood AJJ. Aspirin as an anti-platelet drug. N Engl J Med 1994;330:1287.PubMedCrossRefGoogle Scholar
  19. 19.
    Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661.CrossRefGoogle Scholar
  20. 20.
    Keltz TN, Innerfield M, Gilter B, etal. Dipyridamole-induced myocardial ischemia. JAMA 1987;257:1516.CrossRefGoogle Scholar
  21. 21.
    The ESPS Group. The European Stroke Prevention Study. Principal end points. Lancet 1987;2:1352.Google Scholar
  22. 22.
    CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329.CrossRefGoogle Scholar
  23. 23.
    Bennett R, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773.PubMedCrossRefGoogle Scholar
  24. 24.
    CURE: The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 2001;345:494.CrossRefGoogle Scholar
  25. 25.
    Bhatt DL, Bertrand ME, Berger PB, et al. Meta analysis of randomized and registry with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9.PubMedCrossRefGoogle Scholar
  26. 26.
    CREDO: Steinhubl SR, Berger PB, Mann JT, et al. for the CREDO investigators. Early and sustained dual oral anti-platelet therapy following percutaneous coronary intervention. JAMA 2002 288:2411.PubMedCrossRefGoogle Scholar
  27. 27.
    Sabatine MS, Cannon CP, Gibson CM. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. JAMA 2005; 294:1224–1232.PubMedCrossRefGoogle Scholar
  28. 28.
    COMITT-2 (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1607–1621.CrossRefGoogle Scholar
  29. 29.
    CHARISMA: Lev El, Patel RT, Maresh KJ. The role of dual drug resistance. J Am Coll Cardiol 2006; 47:27–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Bhat DL, Keith AA, Fox KAA, Hacke W, for the CHARISMA Investigators. Prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.CrossRefGoogle Scholar
  31. 31.
    Gebel JM Jr. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient. A neurologist’s view. J Am Coll Cardiol 2005;37:2059–2065.Google Scholar
  32. 32.
    Ben-Yehuda O. Anti-platelet therapies In: Chien K, ed. Molecular Basis of Cardiovascular Disease, A Companion to Braunwald’s Heart Disease. Philadelphia, WB Saunders, 2004.Google Scholar
  33. 33.
    Coller BS. Blockade of platelet GP Ilb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92: 2373–2380.PubMedGoogle Scholar
  34. 34.
    Ben-Yehuda O. Editorial Comment: Upstream/downstream glycoprotein Ilb/IIIa in non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006;47:538–540.PubMedCrossRefGoogle Scholar
  35. 35.
    SYMPHONY Investigators. A randomized comparison of sibrafiban, an oral platelet glycoprotein Ilb/IIIa receptor antagonist, with aspirin for acute coronary syndromes. Lancet 2000;355:337.CrossRefGoogle Scholar
  36. 36.
    CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429.CrossRefGoogle Scholar
  37. 37.
    EPIC Investigators. Use of amonoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956.CrossRefGoogle Scholar
  38. 38.
    EPILOG Investigators. Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;226:1689.CrossRefGoogle Scholar
  39. 39.
    Simoons ML. Effect of glycoprotein Ilb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001;357:1915.PubMedCrossRefGoogle Scholar
  40. 40.
    Anderson RM, Califf RM, Stone GW. Long term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37;2059–2065.PubMedCrossRefGoogle Scholar
  41. 41.
    ESPRIT: Novel dosing regimen ofeptifibatide in planned coronary stent implantation: A randomized placebo controlled trial. Lancet 2000;356:2037.CrossRefGoogle Scholar
  42. 42.
    PURSUIT: Inhibition of platelet glycoprotein Ilb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein Ilb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436.CrossRefGoogle Scholar
  43. 43.
    Roffi M, Chew P, Mukherjee D, et al. Platelet glycoprotein Ilb/IIIa inhibitors reduce mortality in diabetic patients with non ST segment elevation acute coronary syndromes. Circulation 2001; 104:2767.PubMedCrossRefGoogle Scholar
  44. 44.
    Topol EA, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein Ilb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888.PubMedCrossRefGoogle Scholar
  45. 45.
    Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to αvβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000;95:368–374.PubMedGoogle Scholar
  46. 46.
    Thompson RD, Wakelin MW, Larbi KY, et al. Divergent effects of platelet-endothelial cell adhesion molecule-1 and B3 integrin blockade on leukocyte transmigration in vivo. J Immunol 2000;165:426–434.PubMedGoogle Scholar
  47. 47.
    Mickelson JK, Ali MN, Kleiman NS, et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CD1 lb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;33:97–106.PubMedCrossRefGoogle Scholar
  48. 48.
    Neumann F-J, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein Ilb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420–1426.PubMedCrossRefGoogle Scholar
  49. 49.
    PRISM-PLUS: Platelet Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl JMed 1998;338:1488.CrossRefGoogle Scholar
  50. 50.
    Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ilb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879.PubMedCrossRefGoogle Scholar
  51. 51.
    Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med 1983;308:1229.PubMedCrossRefGoogle Scholar
  52. 52a.
    ASSENT-2: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 1999;354:716–722.CrossRefGoogle Scholar
  53. 52b.
    Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605–613.Google Scholar
  54. 53.
    Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447.PubMedCrossRefGoogle Scholar
  55. 54.
    Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction for the ExTRACT-TIMI 25 Investigators. N Engl J Med 2006; 354:1477–1488.PubMedCrossRefGoogle Scholar
  56. 55.
    Kong D, Topol E, Bittl J, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100:2049.PubMedGoogle Scholar
  57. 56.
    ACUITY: Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. Am Heart J 2004;148:764–775.PubMedCrossRefGoogle Scholar
  58. 57.
    Olson RE. Vitamin K. In: Goodhart RS, Shils ME (eds). Modern Nutrition in Health and Disease, 6th ed. Philadelphia, Lea & Febiger, 1980, p 170.Google Scholar
  59. 58.
    Jang IK, Gold HK, Zisking AA, et al. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219.PubMedGoogle Scholar
  60. 59.
    Gibbons RJ, Fuster, V. Therapy for patients with acute coronary syndromes—new opportunities. N Engl J Med 2006;354:1524–1527.PubMedCrossRefGoogle Scholar
  61. 60.
    The OASIS-5: The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354: 1464–1476.CrossRefGoogle Scholar
  62. 61.
    The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The randomized trial. JAMA 2006;295:1519–1530.CrossRefGoogle Scholar
  63. 62.
    Califf RM. Fondaparinux in ST-segment elevation myocardial infarction. The drug, the strategy, the environment, or all of the above? JAMA 2006;295:1579–1580.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction for the ExTRACT-TIMI 25 Investigators. N Engl J Med 2006; 354:1477–1488.PubMedCrossRefGoogle Scholar
  2. Bavry AA, Lincoff AM. Is clopidogrel cardiovascular medicine’s double-edged sword? Circulation 2006; 113:1638–1640.PubMedCrossRefGoogle Scholar
  3. Ben-Yehuda O. Editorial comment: Upstream/downstream glycoprotein Ilb/IIIa in non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006:47:538–540.PubMedCrossRefGoogle Scholar
  4. Califf RM. Fondaparinux in ST-segmentelevationmyocardial infarction. The drug, the strategy, the environment, or all of the above? JAMA 2006;295:1579–1580.PubMedCrossRefGoogle Scholar
  5. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drugeluting stent implantation. JAMA 2007;297:159–168.PubMedCrossRefGoogle Scholar
  6. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006; 48:281–286.PubMedCrossRefGoogle Scholar
  7. Stevens LA, Coresh J, Greene T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations